AMR local indicators - produced by the UKHSA
Help us improve this website
We'd like your feedback on how you use the UKHSA surveillance data.
Take a short survey to tell us what works, what doesn't, and how can we make it better.
Click here to participate.
About the AMR local indicators
Data have been uploaded across six domains: The AMR local indicators are produced by the UKHSA.
- Supporting NHS England Initiatives
- Antimicrobial Resistance (AMR)
- Antibiotic Prescribing
- Healthcare-Associated Infections (HCAI)
- Infection Prevention and Control (IPC)
- Antimicrobial stewardship (AMS)
Antibiotic prescribing and antibiotic resistance are inextricably linked, as overuse and incorrect use of antibiotics are major drivers of resistance. AMR local indicators are publically available data intended to raise awareness of antibiotic prescribing, AMR, HCAI, IPC and AMS; and to facilitate the development of local action plans. The data published in this tool may be used by healthcare staff, commissioners, directors of public health, academics and the public to compare the situation in their local area to the national picture.
For further information about this profile, please click here to download the user guide.
Updated indicators
February 2026 - The following indicators have been updated in the Profile AMR Local Indicators within specific topic (s) and area (s) -
Topic: Antimicrobial Resistance Area: ICB sub-locations level covering the period Q1 2024 - Q4 2025
1. E. coli, blood, testing, carbapenem, quarterly, percentage
2. E. coli, blood, testing, 3rd generation cephalosporin, quarterly
3. E. coli, blood, testing, Ciprofloxacin, quarterly, percentage
4. E. coli, blood, testing, Gentamicin, quarterly, percentage
5. E. coli, blood, testing, Piperacillin/Tazobactam, quarterly, percentage
6. E. coli, urine, testing, trimethoprim, quarterly, percentage, community
7. E. coli, urine, resistance, trimethoprim, quarterly, percentage, community
8. E. coli, urine, testing, nitrofurantoin, quarterly, percentage, community
9. E. coli, urine, resistance, nitrofurantoin, quarterly, percentage, community
10. E.coli, blood, resistance, 1 Antibiotics, rolling quarterly, percentage
11. E.coli, blood, resistance, 3 or more antibiotics classes, rolling quarterly, percentage
12. E.coli, blood, resistance, 3rd generation cephalosporin, rolling quarterly, percentage
13. E.coli, blood, resistance,Ciprofloxacin, rolling quarterly, percentage
14. E.coli, blood, resistance, Gentamicin, rolling quarterly, percentage
15. E.coli, blood, resistance, Piperacillin/Tazobactam, rolling quarterly, percentage
Topic: Antimicrobial Resistance Area: Acute Trusts covering the period Q1 2024 - Q4 2025
1. E. coli, blood, testing, Gentamicin, quarterly, percentage
2. E. coli, blood, testing, carbapenem, quarterly, percentage
3. E. coli, blood, testing, Ciprofloxacin, quarterly, percentage
4. E. coli, blood, testing, piperacillin/tazobactam, quarterly, percentage
5. E. coli, blood, testing, 3rd generation cephalosporin, quarterly, percentage
6. E.coli, blood, resistance, Ciprofloxacin, rolling quarterly, percentage
7. E.coli, blood, resistance, 3rd generation cephalosporin, rolling quarterly, percentage
8. E.coli, blood, resistance, piperacillin/tazobactam, rolling quarterly, percentage
9. E. coli, blood, resistance, Gentamicin, quarterly, percentage
Topic: Antibiotic Prescribing Area: Acute Trusts upto Q3 2025/26 (cy)
- Total antibiotic prescribing DDDs per 1000 admissions; by quarter and trust
AWaRe and broad-spectrum prescribing
- Antibiotic prescribing from the “Watch” and “Reserve” categories of the nationally adapted WHO AWaRE index; DDDs per 1000 admissions by quarter and trust
- Proportion of total antibiotic prescribing from the "Access" category of the nationally adapted WHO AWaRe index; by quarter and acute trust
- Proportion of total antibiotic prescribing from the "Reserve" category of the nationally adapted WHO AWaRe index
- Proportion of total antibiotic prescribing from the "Watch" category of the nationally adapted WHO AWaRe index
- Proportion of total antibiotic prescribing from the "Watch" and "Reserve" categories of the nationally adapted WHO AWaRe index
- Carbapenem prescribing DDDs per 1000 admissions; by quarter and acute trust
Supporting IVOS CQUIN
- Intravenous antibiotic prescribing; DDDs per 1000 admissions by month and NHS Acute Trust
- Proportion of total antibiotic prescribing administered intravenously; by month and NHS Acute Trust
Topic: Healthcare Associated Infections, Area: Sub ICBs or Acute Trusts up to December 2025
Area – ICB sub-locations up to December 2025
1. C. difficile infection 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month
2. C. difficile infection 12-month rolling case counts and rates of community onset-community associated, by Sub ICB Location (SICBL) and month
3. C. difficile infection 12-month rolling case counts and rates of community onset-healthcare associated, by Sub ICB Location (SICBL) and month
4. E. coli bacteraemia 12-month rolling case counts and rates of community-onset, by Sub ICB Location (SICBL) and month
5. E. coli bacteraemia 12-month rolling case counts and rates of hospital-onset, by Sub ICB Location (SICBL) and month
6. E. coli bacteraemia 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month
7. Klebsiella spp. bacteraemia 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month
8. Klebsiella spp. bacteraemia 12-month rolling case counts and rates of hospital-onset, by Sub ICB Location (SICBL) and month
9. Klebsiella spp. bacteraemia 12-month rolling case counts and rates of community-onset, by Sub ICB Location (SICBL) and month
10. MRSA bacteraemia 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month
11. MRSA bacteraemia 12-month rolling case counts and rates of community-onset, by Sub ICB Location (SICBL) and month
12. MRSA bacteraemia 12-month rolling case counts and rates of hospital-onset, by Sub ICB Location (SICBL) and month
13. MSSA bacteraemia 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month
14. MSSA bacteraemia 12-month rolling case counts and rates of community-onset, by Sub ICB Location (SICBL) and month
15. MSSA bacteraemia 12-month rolling case counts and rates of hospital-onset, by Sub ICB Location (SICBL) and month
16. P. aeruginosa bacteraemia 12-month rolling case counts and rates of community-onset, by Sub ICB Location (SICBL) and month
17. P. aeruginosa bacteraemia 12-month rolling case counts and rates of hospital-onset, by Sub ICB Location (SICBL) and month
18. P. aeruginosa bacteraemia 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month
Cases that the UKHSA’s HCAI Data Capture System attributes to a commissioning hub (such as the national commissioning hub, 13Q, or one of the regional Health & Justice commissioning hubs) are not featured in sub ICB Location dashboards but they do still contribute to the highest spatial level—the England national total. This means the England case total may be slightly higher than the sum of all sub ICB Location cases.
Area: Acute Trusts up to December 2025
Data up to December 2025:
1. C. difficile infection 12-month rolling case counts and rates, by reporting acute trust and month
2. C. difficile infection 12-month rolling case counts and rates of community onset-healthcare associated, by reporting acute trust and month
3. C. difficile infection 12-month rolling case counts and rates of hospital onset-healthcare associated cases, by reporting acute trust and month
4. E. coli bacteraemia 12-month rolling case counts and rates of community-onset, by reporting acute trust and month
5. E. coli bacteraemia 12-month rolling case counts and rates, by reporting acute trust and month
6. E. coli bacteraemia 12-month rolling case counts and rates of hospital-onset, by reporting acute trust and month
7. Klebsiella spp. bacteraemia 12-month rolling case counts and rates of community-onset, by reporting acute trust and month
8. Klebsiella spp. bacteraemia 12-month rolling case counts and rates of hospital-onset, by reporting acute trust and month
9. Klebsiella spp. bacteraemia 12-month rolling case counts and rates, by reporting acute trust and month
10. MRSA bacteraemia 12-month rolling case counts and rates, by reporting acute trust and month
11. MRSA bacteraemia 12-month rolling case counts and rates of community-onset, by reporting acute trust and month
12. MRSA bacteraemia 12-month rolling case counts and rates of hospital-onset, by reporting acute trust and month
13. MSSA bacteraemia 12-month rolling case counts and rates of hospital-onset, by reporting acute trust and month
14. MSSA bacteraemia 12-month rolling case counts and rates of community-onset, by reporting acute trust and month
15. MSSA bacteraemia 12-month rolling case counts and rates, by reporting acute trust and month
16. P. aeruginosa bacteraemia 12-month rolling case counts and rates of community-onset, by reporting acute trust and month
17. P. aeruginosa bacteraemia 12-month rolling case counts and rates, by reporting acute trust and month
18. P. aeruginosa bacteraemia 12-month rolling case counts and rates of hospital-onset, by reporting acute trust and month
For all acute trust indicators above, if an acute trust’s data is unavailable for the entire period (e.g. South Tyneside) this is because it was involved in a trust merger and no longer exists today; its data both before & after the merger event will have been added to the trust it merged into (i.e. South Tyneside and Sunderland). We are unable to remove these non-existent trusts from Area dropdown lists (when Area type = ‘Acute Trusts’) or tables (when Data view = ‘Compare areas’ and Area type = ‘Acute Trusts’) because other topics within this Fingertips profile may still display these data.
The routine SGSS-DCS audit (that identifies cases entered on the SGSS but missing from the DCS and informs trusts of these) may generate minor increases in historic case numbers following their correction.
January 2026 - The following indicators have been updated in the Profile AMR Local Indicators within specific topic (s) and area (s) -
Topic: Healthcare-Associated Infections (HCAI), Infection Prevention and Control (IPC) Area: All Trust, England
- Surgical Site Infection Hip Prosthesis by acute NHS trust and financial year 2024/25 Crude rate – per 100 procedures
- Surgical Site Infection Knee Prosthesis by acute NHS trust and financial year 2024/25 Crude rate – per 100 procedures
Topic: Antibiotic Prescribing Area: ICB sub-locations up to Q3 2025/26 (cy)
- Total number of prescribed antibiotic items per STAR-PU by quarter
- Total number of prescribed antibiotics items per 1000 resident individuals by quarter
- Percentage of broad - spectrum prescribed antibiotics items (cephalosporin, quinolone and co- amoxiclav class) by quarter
- Twelve-month rolling proportion of trimethoprim class prescribed antibiotic items as a ratio of trimethoprim to nitrofurantoin
- Twelve-month rolling total number of prescribed antibiotic items per 1000 resident individuals per day
- Twelve-month rolling total number of prescribed antibiotic items per STAR-PU
- Twelve-month rolling percentage of prescribed antibiotic items from cephalosporin, quinolone and co-amoxiclav class
Topic: Antibiotic Prescribing Area: GP up to Q3 2025/256 (cy)
- Percentage of broad-spectrum prescribed antibiotic items (cephalosporin, quinolone and co-amoxiclav class) by quarter
- Total number of prescribed antibiotic items per 1000 registered patients by quarter
- Total number of prescribed antibiotic items per STAR-PU by quarter
- Twelve-month rolling proportion of trimethoprim class prescribed antibiotic items as a ratio of trimethoprim to nitrofurantoin
“The method of consultations in the community during the COVID-19 pandemic (from 2020) is likely to be different from the pre-pandemic period. Therefore, comparisons of the data before and during the pandemic should be treated with caution. Also please note that total antibacterial items have reduced over the COVID-19 period and will have had subsequent impacts on antibiotic proportions, where total antibacterial items has been used as the denominator.”
D10 - Adjusted antibiotic prescribing in primary care: NHS 2024 indicator have been updated.
Please do note that indicators that fall under the Topic: Antibiotic Prescribing and Area: Acute Trusts upto Q3 2025/26 (cy) will be updated next month to go LIVE in March 2026.
Topic: Healthcare Associated Infections, Area: Sub ICBs or Acute Trusts up to November 2025
Area – ICB sub-locations up to November 2025
1. C. difficile infection 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month
2. C. difficile infection 12-month rolling case counts and rates of community onset-community associated, by Sub ICB Location (SICBL) and month
3. C. difficile infection 12-month rolling case counts and rates of community onset-healthcare associated, by Sub ICB Location (SICBL) and month
4. E. coli bacteraemia 12-month rolling case counts and rates of community-onset, by Sub ICB Location (SICBL) and month
5. E. coli bacteraemia 12-month rolling case counts and rates of hospital-onset, by Sub ICB Location (SICBL) and month
6. E. coli bacteraemia 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month
7. Klebsiella spp. bacteraemia 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month
8. Klebsiella spp. bacteraemia 12-month rolling case counts and rates of hospital-onset, by Sub ICB Location (SICBL) and month
9. Klebsiella spp. bacteraemia 12-month rolling case counts and rates of community-onset, by Sub ICB Location (SICBL) and month
10. MRSA bacteraemia 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month
11. MRSA bacteraemia 12-month rolling case counts and rates of community-onset, by Sub ICB Location (SICBL) and month
12. MRSA bacteraemia 12-month rolling case counts and rates of hospital-onset, by Sub ICB Location (SICBL) and month
13. MSSA bacteraemia 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month
14. MSSA bacteraemia 12-month rolling case counts and rates of community-onset, by Sub ICB Location (SICBL) and month
15. MSSA bacteraemia 12-month rolling case counts and rates of hospital-onset, by Sub ICB Location (SICBL) and month
16. P. aeruginosa bacteraemia 12-month rolling case counts and rates of community-onset, by Sub ICB Location (SICBL) and month
17. P. aeruginosa bacteraemia 12-month rolling case counts and rates of hospital-onset, by Sub ICB Location (SICBL) and month
18. P. aeruginosa bacteraemia 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month
Cases that the UKHSA’s HCAI Data Capture System attributes to a commissioning hub (such as the national commissioning hub, 13Q, or one of the regional Health & Justice commissioning hubs) are not featured in sub ICB Location dashboards but they do still contribute to the highest spatial level—the England national total. This means the England case total may be slightly higher than the sum of all sub ICB Location cases.
Area: Acute Trusts up to November 2025
1. C. difficile infection 12-month rolling case counts and rates, by reporting acute trust and month
2. C. difficile infection 12-month rolling case counts and rates of community onset-healthcare associated, by reporting acute trust and month
3. C. difficile infection 12-month rolling case counts and rates of hospital onset-healthcare associated cases, by reporting acute trust and month
4. E. coli bacteraemia 12-month rolling case counts and rates of community-onset, by reporting acute trust and month
5. E. coli bacteraemia 12-month rolling case counts and rates, by reporting acute trust and month
6. E. coli bacteraemia 12-month rolling case counts and rates of hospital-onset, by reporting acute trust and month
7. Klebsiella spp. bacteraemia 12-month rolling case counts and rates of community-onset, by reporting acute trust and month
8. Klebsiella spp. bacteraemia 12-month rolling case counts and rates of hospital-onset, by reporting acute trust and month
9. Klebsiella spp. bacteraemia 12-month rolling case counts and rates, by reporting acute trust and month
10. MRSA bacteraemia 12-month rolling case counts and rates, by reporting acute trust and month
11. MRSA bacteraemia 12-month rolling case counts and rates of community-onset, by reporting acute trust and month
12. MRSA bacteraemia 12-month rolling case counts and rates of hospital-onset, by reporting acute trust and month
13. MSSA bacteraemia 12-month rolling case counts and rates of hospital-onset, by reporting acute trust and month
14. MSSA bacteraemia 12-month rolling case counts and rates of community-onset, by reporting acute trust and month
15. MSSA bacteraemia 12-month rolling case counts and rates, by reporting acute trust and month
16. P. aeruginosa bacteraemia 12-month rolling case counts and rates of community-onset, by reporting acute trust and month
17. P. aeruginosa bacteraemia 12-month rolling case counts and rates, by reporting acute trust and month
18. P. aeruginosa bacteraemia 12-month rolling case counts and rates of hospital-onset, by reporting acute trust and month
For all acute trust indicators above, if an acute trust’s data is unavailable for the entire period (e.g. South Tyneside) this is because it was involved in a trust merger and no longer exists today; its data both before & after the merger event will have been added to the trust it merged into (i.e. South Tyneside and Sunderland). We are unable to remove these non-existent trusts from Area dropdown lists (when Area type = ‘Acute Trusts’) or tables (when Data view = ‘Compare areas’ and Area type = ‘Acute Trusts’) because other topics within this Fingertips profile may still display these data.
The routine SGSS-DCS audit (that identifies cases entered on the SGSS but missing from the DCS and informs trusts of these) may generate minor increases in historic case numbers following their correction.
December 2025 - The following indicators have been updated in the Profile AMR Local Indicators within specific topic (s) and area (s) -
Topic: Antimicrobial Resistance Area: ICB sub-locations level covering the period Q4 2023 - Q3 2025 for urine indicators
1. E. coli, blood, testing, carbapenem, quarterly, percentage
2. E. coli, blood, testing, 3rd generation cephalosporin, quarterly
3. E. coli, blood, testing, Ciprofloxacin, quarterly, percentage
4. E. coli, blood, testing, Gentamicin, quarterly, percentage
5. E. coli, blood, testing, Piperacillin/Tazobactam, quarterly, percentage
6. E. coli, urine, testing, trimethoprim, quarterly, percentage, community
7. E. coli, urine, resistance, trimethoprim, quarterly, percentage, community
8. E. coli, urine, testing, nitrofurantoin, quarterly, percentage, community
9. E. coli, urine, resistance, nitrofurantoin, quarterly, percentage, community
10. E.coli, blood, resistance, 1 Antibiotics, rolling quarterly, percentage
11. E.coli, blood, resistance, 3 or more antibiotics classes, rolling quarterly, percentage
12. E.coli, blood, resistance, 3rd generation cephalosporin, rolling quarterly, percentage
13. E.coli, blood, resistance,Ciprofloxacin, rolling quarterly, percentage
14. E.coli, blood, resistance, Gentamicin, rolling quarterly, percentage
15. E.coli, blood, resistance, Piperacillin/Tazobactam, rolling quarterly, percentage
Topic: Antimicrobial Resistance Area: Acute Trusts covering the period Q1 2015 - Q3 2025 for blood indicators
1. E. coli, blood, testing, Gentamicin, quarterly, percentage
2. E. coli, blood, testing, carbapenem, quarterly, percentage
3. E. coli, blood, testing, Ciprofloxacin, quarterly, percentage
4. E. coli, blood, testing, piperacillin/tazobactam, quarterly, percentage
5. E. coli, blood, testing, 3rd generation cephalosporin, quarterly, percentage
6. E.coli, blood, resistance, Ciprofloxacin, rolling quarterly, percentage
7. E.coli, blood, resistance, 3rd generation cephalosporin, rolling quarterly, percentage
8. E.coli, blood, resistance, piperacillin/tazobactam, rolling quarterly, percentage
9. E. coli, blood, resistance, Gentamicin, quarterly, percentage
October 2025 - The following indicators have been updated in the Profile AMR Local Indicators within specific topic (s) and area (s) -
Topic: Antibiotic Prescribing Area: Acute Trusts upto Q2 2025/26 (cy)
Total antibiotic prescribing DDDs per 1000 admissions; by quarter and trust
AWaRe and broad-spectrum prescribing
Antibiotic prescribing from the “Watch” and “Reserve” categories of the nationally adapted WHO AWaRE index; DDDs per 1000 admissions by quarter and trust
Proportion of total antibiotic prescribing from the "Access" category of the nationally adapted WHO AWaRe index; by quarter and acute trust
Proportion of total antibiotic prescribing from the "Reserve" category of the nationally adapted WHO AWaRe index
Proportion of total antibiotic prescribing from the "Watch" category of the nationally adapted WHO AWaRe index
Proportion of total antibiotic prescribing from the "Watch" and "Reserve" categories of the nationally adapted WHO AWaRe index
Carbapenem prescribing DDDs per 1000 admissions; by quarter and acute trust
Topic: Antibiotic Prescribing Area: ICB sub-locations up to Q2 2025/26 (cy)
Total number of prescribed antibiotic items per STAR-PU by quarter
Total number of prescribed antibiotics items per 1000 resident individuals by quarter
Percentage of broad - spectrum prescribed antibiotics items (cephalosporin, quinolone and co- amoxiclav class) by quarter
Twelve-month rolling proportion of trimethoprim class prescribed antibiotic items as a ratio of trimethoprim to nitrofurantoin
Twelve-month rolling total number of prescribed antibiotic items per 1000 resident individuals per day
Twelve-month rolling total number of prescribed antibiotic items per STAR-PU
Twelve-month rolling percentage of prescribed antibiotic items from cephalosporin, quinolone and co-amoxiclav class
Topic: Antibiotic Prescribing Area: GP up to Q2 2025/256 (cy)
Percentage of broad-spectrum prescribed antibiotic items (cephalosporin, quinolone and co-amoxiclav class) by quarter
Total number of prescribed antibiotic items per 1000 registered patients by quarter
Total number of prescribed antibiotic items per STAR-PU by quarter
Twelve-month rolling proportion of trimethoprim class prescribed antibiotic items as a ratio of trimethoprim to nitrofurantoin
“The method of consultations in the community during the COVID-19 pandemic (from 2020) is likely to be different from the pre-pandemic period. Therefore, comparisons of the data before and during the pandemic should be treated with caution. Also please note that total antibacterial items have reduced over the COVID-19 period and will have had subsequent impacts on antibiotic proportions, where total antibacterial items has been used as the denominator.”
D10 - Adjusted antibiotic prescribing in primary care: NHS 2024 indicator have been updated.
Topic: Healthcare Associated Infections, Area: Sub ICBs or Acute Trusts
Area: ICB sub-locations up to October 2025 (monthly indicators)
C. difficile infection 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month
C. difficile infection 12-month rolling case counts and rates of community onset-community associated, by Sub ICB Location (SICBL) and month
C. difficile infection 12-month rolling case counts and rates of community onset-healthcare associated, by Sub ICB Location (SICBL) and month
E. coli bacteraemia 12-month rolling case counts and rates of community-onset, by Sub ICB Location (SICBL) and month
E. coli bacteraemia 12-month rolling case counts and rates of hospital-onset, by Sub ICB Location (SICBL) and month
E. coli bacteraemia 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month
Klebsiella spp. bacteraemia 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month
Klebsiella spp. bacteraemia 12-month rolling case counts and rates of hospital-onset, by Sub ICB Location (SICBL) and month
Klebsiella spp. bacteraemia 12-month rolling case counts and rates of community-onset, by Sub ICB Location (SICBL) and month
MRSA bacteraemia 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month
MRSA bacteraemia 12-month rolling case counts and rates of community-onset, by Sub ICB Location (SICBL) and month
MRSA bacteraemia 12-month rolling case counts and rates of hospital-onset, by Sub ICB Location (SICBL) and month
MSSA bacteraemia 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month
MSSA bacteraemia 12-month rolling case counts and rates of community-onset, by Sub ICB Location (SICBL) and month
MSSA bacteraemia 12-month rolling case counts and rates of hospital-onset, by Sub ICB Location (SICBL) and month
P. aeruginosa bacteraemia 12-month rolling case counts and rates of community-onset, by Sub ICB Location (SICBL) and month
P. aeruginosa bacteraemia 12-month rolling case counts and rates of hospital-onset, by Sub ICB Location (SICBL) and month
P. aeruginosa bacteraemia 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month
Cases that the UKHSA’s HCAI Data Capture System attributes to a commissioning hub (such as the national commissioning hub, 13Q, or one of the regional Health & Justice commissioning hubs) are not featured in sub ICB Location dashboards but they do still contribute to the highest spatial level—the England national total. This means the England case total may be slightly higher than the sum of all sub ICB Location cases.
Area: Acute Trusts up to October 2025/26 fy Q2 (monthly & quarterly indicators, respectively)
C. difficile infection 12-month rolling case counts and rates, by reporting acute trust and month
C. difficile infection 12-month rolling case counts and rates of community onset-healthcare associated, by reporting acute trust and month
C. difficile infection 12-month rolling case counts and rates of hospital onset-healthcare associated cases, by reporting acute trust and month
E. coli bacteraemia 12-month rolling case counts and rates of community-onset, by reporting acute trust and month
E. coli bacteraemia 12-month rolling case counts and rates, by reporting acute trust and month
E. coli bacteraemia 12-month rolling case counts and rates of hospital-onset, by reporting acute trust and month
Klebsiella spp. bacteraemia 12-month rolling case counts and rates of community-onset, by reporting acute trust and month
Klebsiella spp. bacteraemia 12-month rolling case counts and rates of hospital-onset, by reporting acute trust and month
Klebsiella spp. bacteraemia 12-month rolling case counts and rates, by reporting acute trust and month
MRSA bacteraemia 12-month rolling case counts and rates, by reporting acute trust and month
MRSA bacteraemia 12-month rolling case counts and rates of community-onset, by reporting acute trust and month
MRSA bacteraemia 12-month rolling case counts and rates of hospital-onset, by reporting acute trust and month
MSSA bacteraemia 12-month rolling case counts and rates of hospital-onset, by reporting acute trust and month
MSSA bacteraemia 12-month rolling case counts and rates of community-onset, by reporting acute trust and month
MSSA bacteraemia 12-month rolling case counts and rates, by reporting acute trust and month
P. aeruginosa bacteraemia 12-month rolling case counts and rates of community-onset, by reporting acute trust and month
P. aeruginosa bacteraemia 12-month rolling case counts and rates, by reporting acute trust and month
P. aeruginosa bacteraemia 12-month rolling case counts and rates of hospital-onset, by reporting acute trust and month
Stool specimens examined for diagnosis of C. difficile infection per 1,000 bed-days carries out by reporting acute trust and quarter
Blood culture sets per 1,000 bed-days performed by reporting acute trust and quarter
For all acute trust indicators above, if an acute trust’s data is unavailable for the entire period (e.g. South Tyneside) this is because it was involved in a trust merger and no longer exists today; its data both before & after the merger event will have been added to the trust it merged into (i.e. South Tyneside and Sunderland). We are unable to remove these non-existent trusts from Area dropdown lists (when Area type = ‘Acute Trusts’) or tables (when Data view = ‘Compare areas’ and Area type = ‘Acute Trusts’) because other topics within this Fingertips profile may still display these data.
The routine SGSS-DCS audit (that identifies cases entered on the SGSS but missing from the DCS and informs trusts of these) may generate minor increases in historic case numbers following their correction.
We have updated the indicator name from "C. difficile toxin tests per 1,000 bed-days carried out by reporting acute trust and financial quarter" to "Stool specimens examined for diagnosis of CDI per 1,000 bed-days carried out by reporting acute trust and financial quarter" as the former metadata was an out-of-date description. The data has not changed.
Interventions to reduce AMR
There are a number of actions that can be taken to reduce the burden of AMR. These include improved antibiotic prescribing as well as enhanced infection prevention and control, both for healthcare-associated and community-onset infections. The AMR resource handbook identifies current national policy, guidance and supporting materials in relation to antimicrobial stewardship and the infection prevention and control of healthcare associated infections in order to aid the reduction of antimicrobial resistance.